Evidence supporting the use of: Phytocannabinoid (unspecified)
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Phytocannabinoids, particularly those derived from the Cannabis sativa plant (such as THC and CBD), have a scientifically established role in supporting or treating certain symptoms of Multiple Sclerosis (MS). Evidence is strongest for their use in managing spasticity and some pain symptoms associated with MS. Several randomized controlled trials and systematic reviews have found that nabiximols (Sativex), an oromucosal spray containing a 1:1 ratio of THC and CBD, can significantly reduce spasticity in patients with MS who have not responded adequately to other anti-spasticity medications. The European Medicines Agency and regulatory agencies in other countries have approved nabiximols for this indication. There is also some evidence to suggest a benefit in pain management and sleep quality, though these effects are generally modest. However, phytocannabinoids do not appear to modify the underlying disease course or progression of MS. Adverse effects, including dizziness and fatigue, are not uncommon. Overall, the use of phytocannabinoids for symptomatic management in MS is supported by a moderate to strong level of scientific evidence, particularly for spasticity, but not as a disease-modifying therapy. Guidelines from several neurological and medical organizations recognize their use as an option for select patients.

More about Phytocannabinoid (unspecified)
More about Multiple Sclerosis

Products containing Phytocannabinoid (unspecified)

We currently have no products on Caring Sunshine that contain this ingredient.